Evidence map›Paper›PMID 41701649›Full record

ArticleThe Journal of clinical investigation2026

A CD57+CD8+ T cell subset links T cell cytotoxicity to fibrotic lung disease in systemic sclerosis.

Takanori Sasaki, Ye Cao, John M Sowerby, Kazuhiko Higashioka, Kathryne E Marks, Mehreen Elahee, Mari Kamiya, Paul F Dellaripa, Richard I Ainsworth, Kimberly E Taylor and 5 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takanori SasakiDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.
Ye CaoDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.
John M SowerbyDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.
Kazuhiko HigashiokaDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.
Kathryne E MarksDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.
Mehreen ElaheeDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.
Mari KamiyaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, BWH and Harvard Medical School, Boston, Massachusetts, USA.
Paul F DellaripaDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.
Richard I AinsworthDepartment of Medicine, Division of Rheumatology, and.
Kimberly E TaylorDivision of Rheumatology, Department of Medicine, and.
Nunzio BottiniDepartment of Medicine, Division of Rheumatology, and.
Paul WoltersDivision of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, UCSF, San Francisco, California, USA.
Edy Y KimDivision of Pulmonary and Critical Care Medicine, Department of Medicine, BWH and Harvard Medical School, Boston, Massachusetts, USA.
Francesco BoinDepartment of Medicine, Division of Rheumatology, and.
Deepak A RaoDivision of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital (BWH) and Harvard Medical School, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc); however, the immunopathologic mechanisms driving lung disease in SSc are unclear. T cells have been implicated as a likely driver of lung injury in SSc. Here, we evaluated T cells in the blood of patients with SSc-ILD and identified a specific population of cytotoxic CD8+ T cells that was expanded in patients with SSc-ILD. Cytotoxic effector memory CD8+ T cells marked by CD57 expression were preferentially expanded in patients with SSc-ILD compared with patients with SSc but no ILD and control individuals and showed prominent clonal expansion. These CD57+ T effector memory (Tem) cells differed from T effector memory cells reexpressing CD45RA (Temra) transcriptomically and functionally, with cytotoxic function that was enhanced by CD155 engagement of the costimulatory receptor CD226. We performed immunostaining of lung tissue samples obtained from independent patients with SSc-ILD (biopsy or explant) and confirmed the presence of CD57+ Tem cells. In parallel, we analyzed publicly available lung scRNA-seq datasets from multiple ILD cohorts and identified endothelial cells as a likely source of CD155 for the activation of CD57+ cytotoxic T cells. Together, the results implicate a CD57+ cytotoxic CD8+ T cell population as a potential mediator of lung injury in SSc-ILD.

Indexed as

CD57 AntigensCD8-Positive T-LymphocytesLung Diseases, InterstitialPulmonary FibrosisScleroderma, SystemicT-Lymphocytes, CytotoxicT-Lymphocyte SubsetsAgedFemaleHumansMaleMiddle AgedCD57 AntigensAutoimmunityImmunologyT cells

Identifiers

PMID41701649
PMCPMC13132381

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.